摘要
目的研究甲状腺微小乳头状癌(PTMC)患者癌组织中细胞角蛋白19(CK19)、甲状腺过氧化物酶(TPO)、Galectin-3和Survivin蛋白表达水平及诊断价值。方法采用免疫组织化学方法对2013年2月—2015年3月接受手术治疗的110例甲状腺肿瘤患者(PTMC 50例,甲状腺良性病变60例)标本进行检测,观察CK19、TPO、Galectin-3和Survivin在甲状腺病变组织的表达情况。结果 PTMC组织CK19、Survivin和Galectin-3的表达阳性率高于甲状腺良性病变组织(P<0.01),而TPO的表达阳性率低于甲状腺良性病变组织(P<0.01)。CK19诊断PTMC的灵敏度、特异度和准确性分别为98.0%、78.3%和87.3%,Galectin-3分别为98.0%、76.7%和86.4%,Survivin分别为86.0%、98.3%和92.7%,TPO分别为90.0%、98.3%和94.5%。结论 CK19、Survivin、Galectin-3蛋白和TPO联合使用鉴别PTMC与甲状腺良性病变的效果更好。
Objective To investigate expressions of cytokeratinl9 （CK19） , thyroid peroxidase （TPO） , Galectin- 3 and Survivin in papillary thyroid microcarcinoma （PTMC） and their diagnostic values. Methods Immunohistochemical method was used to detect 110 samples of thyroid tumor （50 patients with PTMC, 60 patients with thyroid benign lesions）, who underwent surgeries during February 2013 and March 2015. Expressions of CK19, TPO, Galectin-3 and Survivin in thyroid lesion tissues were observed. Results In PTMC tissues, positive expression rates of CK19, Survivin and Galectin- 3 were significantly higher （P 〈 0. 01 ） , while TPO positive expression rate was significantly lower than those in benign thy- roid lesion tissues （P 〈 0. 01 ）. The sensitivity, speeifieity and accuracy of CKI 9 in diagnosis of PTMC were 98% , 78.3% and 87.3% respectively; the sensitivity, specificity and accuracy of Galectin-3 in diagnosis of PTMC were 98% , 76.7% and 86.4% respectively; Survivin were 86% , 98.3% and 92.7% respectively; the sensitivity, specificity and accuracy of TPO in diagnosis of PTMC were 90% , 98.3% and 94.5% respectively. Conclusion Combination use of CK19, Survivin, Galectin-3 and TPO in identification of PTMC and thyroid benign lesions can achieve better effect.
出处
《解放军医药杂志》
CAS
2017年第6期48-50,共3页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
湖北省自然科学基金项目(2014CFC1028)
